MA33693B1 - Dérivés de pyrazole qui modulent la stéroyl-coa désaturase - Google Patents

Dérivés de pyrazole qui modulent la stéroyl-coa désaturase

Info

Publication number
MA33693B1
MA33693B1 MA34807A MA34807A MA33693B1 MA 33693 B1 MA33693 B1 MA 33693B1 MA 34807 A MA34807 A MA 34807A MA 34807 A MA34807 A MA 34807A MA 33693 B1 MA33693 B1 MA 33693B1
Authority
MA
Morocco
Prior art keywords
derivatives
modulate
coa
steroil
perazol
Prior art date
Application number
MA34807A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Natalie Dales
Jianmin Fu
Qi Jia
Natalia Pokrovskaia
Shaoyi Sun
Zaihui Zhang
Original Assignee
Novartis Ag
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43066810&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33693(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Xenon Pharmaceuticals Inc filed Critical Novartis Ag
Publication of MA33693B1 publication Critical patent/MA33693B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA34807A 2009-10-01 2012-04-26 Dérivés de pyrazole qui modulent la stéroyl-coa désaturase MA33693B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24763409P 2009-10-01 2009-10-01
PCT/EP2010/064672 WO2011039358A1 (en) 2009-10-01 2010-10-01 Pyrazole derivatives which modulate stearoyl-coa desaturase

Publications (1)

Publication Number Publication Date
MA33693B1 true MA33693B1 (fr) 2012-10-01

Family

ID=43066810

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34807A MA33693B1 (fr) 2009-10-01 2012-04-26 Dérivés de pyrazole qui modulent la stéroyl-coa désaturase

Country Status (23)

Country Link
US (1) US20130011361A1 (enExample)
EP (1) EP2483264A1 (enExample)
JP (1) JP2013506638A (enExample)
KR (1) KR20120080226A (enExample)
CN (1) CN102574841A (enExample)
AU (1) AU2010302577A1 (enExample)
BR (1) BR112012007509A2 (enExample)
CA (1) CA2776294A1 (enExample)
CL (1) CL2012000797A1 (enExample)
CO (1) CO6761294A2 (enExample)
CR (1) CR20120134A (enExample)
EA (1) EA201200545A1 (enExample)
EC (1) ECSP12011837A (enExample)
IL (1) IL218294A0 (enExample)
IN (1) IN2012DN01913A (enExample)
MA (1) MA33693B1 (enExample)
MX (1) MX2012003938A (enExample)
PE (1) PE20121439A1 (enExample)
PH (1) PH12012500648A1 (enExample)
SG (1) SG178869A1 (enExample)
TN (1) TN2012000085A1 (enExample)
WO (1) WO2011039358A1 (enExample)
ZA (1) ZA201201390B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2850836A1 (en) 2011-10-15 2013-04-18 Genentech, Inc. Methods of using scd1 antagonists
CN110099898B (zh) 2016-10-24 2023-07-25 优曼尼蒂治疗公司 化合物及其用途
CN110392833A (zh) 2017-01-06 2019-10-29 优曼尼蒂治疗公司 治疗神经病症的方法
WO2019084157A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. COMPOUNDS AND USES THEREOF
CN112312913B (zh) 2018-03-23 2024-03-08 詹森药业有限公司 化合物和其用途
CN113906019A (zh) 2019-01-24 2022-01-07 优曼尼蒂治疗公司 化合物及其用途
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
GB202012969D0 (en) * 2020-08-19 2020-09-30 Univ Of Oxford Inhibitor compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058360A2 (en) 1999-03-29 2000-10-05 Uutech Limited Analogs of gastric inhibitory peptide and their use for treatment of diabetes
CZ296858B6 (cs) 1999-09-28 2006-07-12 Bayer Corporation Agonisté receptoru 3 (R3) hypofyzárního peptidu aktivujícího adenylátcyklázu (PACAP) a jejich farmaceutické pouzití
ATE475718T1 (de) 2000-02-24 2010-08-15 Xenon Pharmaceuticals Inc Stearoyl-coa-desaturase zur identifizierung von triglyceridreduktionstherapeutika
US7232662B2 (en) 2000-09-26 2007-06-19 Xenon Pharmaceuticals Inc. Methods and compositions employing a novel stearoyl-CoA desaturase-hSCD5
CA2580855A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
JP4958784B2 (ja) * 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド ステアロイル−CoAデサチュラーゼ酵素によって媒介される疾患の処置のための複素環誘導体
WO2007046867A2 (en) * 2005-05-19 2007-04-26 Xenon Pharmaceuticals Inc. Piperidine derivatives and their uses as therapeutic agents
RU2009109147A (ru) * 2006-08-15 2010-09-27 Новартис АГ (CH) Органические соединения
RU2009110254A (ru) * 2006-08-24 2010-09-27 Новартис АГ (CH) Производные 2-(пиразин-2-ил)тиазола и 2-(1н-пиразол-3-ил)тиразола и связанные с ним соединения в качестве ингибиторов стеароил-соа десатуразы для лечения метаболических, сердечно-сосудистых и других нарушений
EP2066664A1 (en) * 2006-09-22 2009-06-10 Novartis AG Heterocyclic organic compounds
US8068738B2 (en) * 2007-02-21 2011-11-29 Tte Technology, Inc. System and method for decoding infra-red (IR) signals
MX2010009158A (es) * 2008-02-20 2010-09-24 Novartis Ag Inhibidores heterociclicos de estearoil-coa-desaturasa.

Also Published As

Publication number Publication date
EP2483264A1 (en) 2012-08-08
EA201200545A1 (ru) 2012-12-28
TN2012000085A1 (en) 2013-09-19
JP2013506638A (ja) 2013-02-28
WO2011039358A1 (en) 2011-04-07
CN102574841A (zh) 2012-07-11
CA2776294A1 (en) 2011-04-07
KR20120080226A (ko) 2012-07-16
ZA201201390B (en) 2012-10-31
CR20120134A (es) 2012-05-17
MX2012003938A (es) 2012-08-03
BR112012007509A2 (pt) 2016-11-22
CO6761294A2 (es) 2013-09-30
PE20121439A1 (es) 2012-11-06
CL2012000797A1 (es) 2013-08-09
IL218294A0 (en) 2012-04-30
SG178869A1 (en) 2012-04-27
IN2012DN01913A (enExample) 2015-07-24
US20130011361A1 (en) 2013-01-10
PH12012500648A1 (en) 2012-11-12
AU2010302577A1 (en) 2012-03-15
ECSP12011837A (es) 2012-06-29

Similar Documents

Publication Publication Date Title
MA30655B1 (fr) Composes organiques.
MA33693B1 (fr) Dérivés de pyrazole qui modulent la stéroyl-coa désaturase
MA32150B1 (fr) Inhibiteurs heterocycliques de la stearoyl-coa desaturase
MA31874B1 (fr) Inhibiteurs de bêta-lactamases
TNSN07305A1 (fr) Agonistes de pyy et leurs utilisations
MX2009006728A (es) Heterociclos de 5 miembros 2-sustituidos como inhibidores de scd.
MA31433B1 (fr) Inhibiteurs de la p70 s6 kinase
MA30945B1 (fr) Anticorps anti-tat226 et immunoconjugués
WO2009156484A3 (en) Organic compounds
MA34767B1 (fr) Compositions et procédés pour la modulation de fxr
MA33197B1 (fr) Inhibiteurs de tripeptide époxy cétone protéases cristallines
MX2008012400A (es) Azolopirimidinas como inhibidores de actividad de cannabinoide 1.
EA200701036A1 (ru) Лактамные соединения и их применение в качестве фармацевтических препаратов
PH12012500809A1 (en) Methods and compositions for treating cancer
MX2009003080A (es) Compuestos organicos heterociclicos.
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA33604B1 (fr) Composés et compositions en tant qu'inhibiteurs de protéine kinase
MA31764B1 (fr) Composés et compositions en tant que modulateurs de l'activité de gpr119
MX2007009356A (es) Compuestos y composiciones como moduladores de ppar.
MA33323B1 (fr) Thérapie adjuvante de cancer
EP2164978A4 (en) COMPOSITIONS AND METHODS FOR MODULATING ADAMTS13 ACTIVITY
EP2340258A4 (en) PROCESS FOR THE SYNTHESIS AND APPLICATIONS OF INHIBITORS OF GHRELIN-O-ACYLTRANSFERASE AS POTENTIAL THERAPEUTIC AGENTS AGAINST OBESITAS AND DIABETES
TN2014000195A1 (fr) 2-thiopyrimidinones
TW200602330A (en) Compounds and compositions as PPAR modulators
TW200600505A (en) Compounds and compositions as ppar modulators